Compare Gilead Sciences, Inc. (GILD) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nomura Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while Nomura Holdings Inc trades at $10.05 (market cap $29.38B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| GILD | NMR | |
|---|---|---|
Market Cap | $163.51B | $29.38B |
Sector | Health | Financials |
52-Week High | $155.80 | $10.04 |
52-Week Low | $108.22 | $6.30 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Nomura Holdings (NMR) trades at $9.85, up 1.03% with a bullish technical outlook from moving averages. The stock shows strong fundamentals with a P/E of 13.65, net income margin of 19.66%, and record annual profit in 2025. Recent news highlights expansion in wholesale revenue and strategic acquisitions, including a U.S. fund management push and digital asset subsidiary progress.
Outlook is positive due to valuation discounts versus peers and ROE expansion potential, but risks include earnings misses in recent quarters and rising debt-to-asset ratios. Analysts are mixed with 33% buy ratings, suggesting cautious optimism amid integration costs from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
